Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | LPL | P06858 | 2/20 | 0.48 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.46 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290161 | 0.90 | PPARA (0.49) | PPARAPPARGLPLLIPGCYSLTR2 | |
| SCHEMBL28025268 | 0.89 | PPARA (0.48) | PPARAPPARGLPLLIPGCYSLTR2 | |
| SCHEMBL17571629 | 0.86 | PPARA (0.46) | PPARAPPARGLPLLIPGCYSLTR2 | |
| SCHEMBL4390456 | 0.85 | AKR1C3 (0.46) | KDM4AAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL30375642 | 0.85 | PPARA (0.52) | PPARAPPARGLPLLIPGCYSLTR2 | |
| SCHEMBL290381 | 0.84 | PPARA (0.51) | PPARAPPARGLPLLIPGCYSLTR2 | |
| SCHEMBL4389616 | 0.84 | NOS1 (0.45) | KDM4AAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL16050558 | 0.82 | PPARA (0.50) | PPARAPPARGLPLLIPGCYSLTR2 | |
| SCHEMBL11498518 | 0.82 | PPARA (0.50) | PPARAPPARGLPLLIPGCYSLTR2 | |
| SCHEMBL10525905 | 0.80 | CYSLTR2 (0.56) | CYSLTR2CYSLTR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095102-A1 | Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-19 | — | — | US | claimed |
| EP-2427417-A1 | SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | claimed |
| US-20120095102-A1 | Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-19 | — | — | US | disclosed |
| EP-2427417-A1 | SALTS OF 3-PENTYLPHENYLACETIC ACID AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095102-A1 | Salts of 3-Pentylphenylacetic Acid and Pharmaceutical Uses Thereof | GLS, REN, PTP4A3 | PPARA 305/4885PPARG 864/4885KDM4A 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.